| | Publication Year | Title | Author(s) |
| 221 | 1-Jun-2022 | Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. | Majem, Margarita; Goldman, Jonathan W; John, Thomas ; Grohe, Christian; Laktionov, Konstantin; Kim, Sang-We; Kato, Terufumi; Vu, Huu Vinh; Lu, Shun; Li, Shanqing; Lee, Kye Young; Akewanlop, Charuwan; Yu, Chong-Jen; de Marinis, Filippo; Bonanno, Laura; Domine, Manuel; Shepherd, Frances A; Atagi, Shinji; Zeng, Lingmin; Kulkarni, Dakshayini; Medic, Nenad; Tsuboi, Masahiro; Herbst, Roy S; Wu, Yi-Long |
| 222 | 17-Nov-2021 | hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. | Aughton, Karen; Elander, Nils O; Evans, Anthony; Jackson, Richard; Campbell, Fiona; Costello, Eithne; Halloran, Christopher M; Mackey, John R; Scarfe, Andrew G; Valle, Juan W; Carter, Ross; Cunningham, David; Tebbutt, Niall C ; Goldstein, David; Shannon, Jennifer; Glimelius, Bengt; Hackert, Thilo; Charnley, Richard M; Anthoney, Alan; Lerch, Markus M; Mayerle, Julia; Palmer, Daniel H; Büchler, Markus W; Ghaneh, Paula; Neoptolemos, John P; Greenhalf, William |
| 223 | 17-Nov-2009 | High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. | Azad, Arun A; Chionh, Fiona; Scott, Andrew M ; Lee, Szeting T; Berlangieri, Salvatore U ; White, Shane C; Mitchell, Paul L R |
| 224 | 31-Mar-2022 | High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres. | Connolly, Elizabeth A; Weickhardt, Andrew J ; Grimison, Peter; Asher, Rebecca; Heller, Gillian Z; Lewin, Jeremy; Liow, Elizabeth; Toner, Guy; Tung, Iris L Y; Tran, Ben; Hill, Sean; Walpole, Euan; McKenzie, Jane; Kuchel, Anna; Goh, Jeffrey; Forgeson, Garry; Tan, Alvin; Joshi, Abhishek; Wickham, Alistair; Tan, Hsiang; Wang, Yang; Winstanley, Mark A; Hamad, Nada; Wong, Vanessa |
| 225 | Mar-2019 | Hospital lung surgery volume and patient outcomes. | Thai, Alesha A; Stuart, E; Te Marvelde, L; Milne, R L; Knight, S ; Whitfield, K; Mitchell, Paul L R |
| 226 | Dec-2018 | Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response. | Sud, S; O'Callaghan, C ; Jonker, C; Karapetis, C; Price, T; Tebbutt, Niall C ; Shapiro, J; Van Hazel, G; Pavlakis, N; Gibbs, P; Jeffrey, M; Siu, L; Gill, S; Wong, R ; Jonker, D; Tu, D; Goodwin, R |
| 7 | Jun-2020 | Hypocalcaemia following denosumab in prostate cancer: a clinical review. | Lau, Lik-Hui; Cliff, Edward R S; Wong, Vanessa ; Wong, Henry; Torkamani, Niloufar ; Eer, Audrey; Weickhardt, Andrew; Grossmann, Mathis |
| 8 | 29-Dec-2015 | Hypopharyngeal large cell neuroendocrine carcinoma | Lee, Wei-I; Ameratunga, Malaka; du Plessis, Justin; Gan, Hui K |
| 9 | 15-Jan-2013 | Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study. | Chang, Joe H; Wada, Morikatsu ; Anderson, Nigel J; Lim Joon, Daryl ; Lee, Sze Ting ; Gong, Sylvia J; Gunawardana, Dishan H; Sachinidis, John; O'Keefe, Graeme J; Gan, Hui K ; Khoo, Vincent; Scott, Andrew M |
| 10 | 10-Nov-2022 | Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy. | Cao, Zhipeng; Burvenich, Ingrid J; Zhao, Kening; Senko, Clare ; Glab, Jason; Fogliaro, Renee; Liu, Zhanqi; Jose, Irvin; Puthalakath, Hamsa; Hoogenraad, Nick J; Osellame, Laura D; Scott, Andrew M |
| 11 | Aug-2021 | The IHC4+C score: an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020? | Harel, Nadav; Cheema, Steven ; Williams, David S ; Ireland-Jenkin, Kerryn ; Fancourt, Tineke ; Dodson, Andrew; Yeo, Belinda |
| 12 | 1-Jun-2022 | Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. | Navani, Vishal; Ernst, Matthew; Wells, J Connor; Yuasa, Takeshi; Takemura, Kosuke; Donskov, Frede; Basappa, Naveen S; Schmidt, Andrew ; Pal, Sumanta K; Meza, Luis; Wood, Lori A; Ernst, D Scott; Szabados, Bernadett; Powles, Thomas; McKay, Rana R; Weickhardt, Andrew J ; Suarez, Cristina; Kapoor, Anil; Lee, Jae Lyun; Choueiri, Toni K; Heng, Daniel Y C |
| 13 | 2021 | Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results. | Balasubramanian, Adithya ; Onggo, James; Gunjur, Ashray ; John, Thomas ; Parakh, Sagun |
| 14 | 2017 | The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. | Thapa, Bibhusal ; Salcedo, Adriana; Lin, Xihui; Walkiewicz, Marzena; Murone, Carmel ; Ameratunga, Malaka; Asadi, Khashayar ; Deb, Siddhartha; Barnett, Stephen A ; Knight, Simon; Mitchell, Paul L R ; Watkins, D Neil; Boutros, Paul C; John, Thomas |
| 15 | May-2023 | Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. | Manos, Kate ; Chong, Geoffrey ; Keane, Colm; Lee, Sze Ting ; Smith, Charmaine; Churilov, Leonid ; McKendrick, Joseph; Renwick, William; Blombery, Piers; Burgess, Melinda; Nelson, Niles Elizabeth; Fancourt, Tineke ; Hawking, Joanne; Lin, Wendi; Scott, Andrew M ; Barraclough, Allison ; Wight, Joel C ; Grigg, Andrew P ; Fong, Chun Yew ; Hawkes, Eliza A |
| 16 | 18-Nov-2022 | ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. | Hegi-Johnson, Fiona; Rudd, Stacey E; Wichmann, Christian; Akhurst, Tim; Roselt, Peter; Trinh, Jenny; John, Thomas ; Devereux, Lisa; Donnelly, Paul S; Hicks, Rod; Scott, Andrew M ; Steinfort, Daniel; Fox, Stephen; Blyth, Benjamin; Parakh, Sagun ; Hanna, Gerard G; Callahan, Jason; Burbury, Kate; MacManus, Michael |
| 17 | 6-Oct-2016 | Immunotherapy for malignant mesothelioma: reality check | Thapa, Bibhusal ; Watkins, D Neil; John, Thomas |
| 18 | 1-Dec-2007 | Immunotherapy of advanced or metastatic melanoma. | Cebon, Jonathan S ; Gedye, Craig; John, Thomas ; Davis, Ian D |
| 19 | Sep-2020 | Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. | Klein, Oliver ; Kee, Damien ; Markman, Ben; Michael, Michael; Underhill, Craig; Carlino, Matteo S; Jackett, Louise A ; Lum, Caroline; Scott, Clare; Nagrial, Adnan; Behren, Andreas; So, Jane Y; Palmer, Jodie ; Cebon, Jonathan S |
| 20 | Nov-2020 | Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer. | Kanjanapan, Yada; Lok, Sheau Wen; Gibbs, Peter; De Boer, Richard; Yeo, Belinda ; Greenberg, Sally; Barnett, Frances; Knott, Louise; Richardson, Gary; Wong, Rachel; Nottage, Michelle; Collins, Ian M; Torres, Javier; Lombard, Janine; Johns, Julie; Harold, Michael; Malik, Laeeq |